Lifemd Inc Stock Price, News & Analysis

LifeMD (NASDAQ: LFMD) appointed Dr. Tara Scott as ambassador and clinical advisor for its women’s health program on October 22, 2025. Dr. Scott, a board-certified OB/GYN and menopause specialist with 25+ years of clinical and teaching experience, will guide outreach, education, and program development across perimenopause, menopause, hormonal balance, bone density, metabolism, and long-term wellness.

The virtual program offers tiered subscriptions, lab access, mail-order prescriptions, dietitian support, and LifeMD+ membership with 24/7 primary and urgent care. The release cites underdiagnosis: one in four women seek menopause treatment and women represent 80% of osteoporosis cases with two-thirds undiagnosed, and references a BCG estimate of a $60–70 billion market opportunity by 2030.

LifeMD (NASDAQ:LFMD) has expanded its collaboration with Novo Nordisk to offer Ozempic® at $499 per month to eligible self-pay patients through its virtual care platform. The offering targets uninsured patients and those whose insurance doesn't cover GLP-1 therapies.

Through integration with NovoCare® Pharmacy, patients can access all FDA-approved dose strengths of Ozempic® and Wegovy® within LifeMD's comprehensive care platform, which includes virtual consultations, clinical support, diagnostic testing, and pharmacy coordination. The platform also provides access to Lilly's Zepbound® through integration with LillyDirect pharmacy provider.

Ozempic® is FDA-approved for type 2 diabetes, which affects approximately 36 million Americans. This collaboration aims to improve accessibility to authentic, FDA-approved GLP-1 treatments at competitive self-pay prices.

LifeMD (NASDAQ:LFMD), a virtual primary care services provider, announced its participation in the ROTH 4th Annual Healthcare Opportunities Conference. The event will take place on October 9, 2025 at the Metropolitan Club in New York City. The company's management team will conduct one-on-one meetings with investors during the conference.

LifeMD (NASDAQ:LFMD), a virtual primary care services provider, has declared its quarterly dividend for holders of its 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP). The company will distribute a cash dividend of $0.5546875 per share to preferred stockholders of record as of October 3, 2025, with the payment scheduled for October 15, 2025.

LifeMD (Nasdaq: LFMD) has expanded its affiliated pharmacy services to include non-sterile compounding capabilities for oral and topical medications. This enhancement follows the August 2024 launch of their commercial pharmacy, which can process up to 5,000 prescriptions daily.

The expanded facility will enable LifeMD to formulate customized medications, including allergen-free and combination products not commercially available. Operating under FDA's 503A designation, the pharmacy is currently licensed in 13 states and aims to secure licenses across all 50 states within 12 months.

This strategic expansion supports LifeMD's core service areas in men's and women's health and dermatology while reducing third-party provider dependence and improving operational efficiency.

LifeMD (NASDAQ:LFMD), a virtual primary care services provider, has announced its participation in three major investor conferences in September 2025:

The company will attend the Cantor Fitzgerald Global Healthcare Conference (Sept 3-5) featuring a fireside chat, the H.C. Wainwright Global Investment Conference (Sept 8-10) with an on-demand presentation, and the Lake Street Capital Markets Best Ideas Growth Conference (Sept 11). Management will be available for one-on-one meetings with investors at all three events.

LifeMD (NASDAQ:LFMD), a virtual primary care services provider, reported strong Q2 2025 financial results with total revenue increasing 23% year-over-year to $62.2 million. The company's telehealth segment showed impressive growth, with revenue up 30% to $48.6 million and adjusted EBITDA surging 560% to $3.4 million.

Key operational highlights include reaching 297,000 active telehealth subscribers, launching a nationwide behavioral health offering, and acquiring a virtual women's health brand. The company generated over $8 million in operating cash flow and exited the quarter with $36.2 million in cash, having fully repaid all senior debt.

However, LifeMD revised its full-year 2025 guidance downward due to temporary challenges in its Rex MD business, now expecting total revenue of $250-255 million and adjusted EBITDA of $27-29 million, compared to previous guidance of $268-275 million and $31-33 million respectively.

Medifast (NYSE: MED) reported challenging second quarter 2025 results, with revenue declining 37.4% to $105.6 million from $168.6 million in Q2 2024. The company's active OPTAVIA coaches decreased 32.7% to 22,800, while revenue per coach fell to $4,630. Despite operational challenges, Medifast maintained a strong balance sheet with $162.7 million in cash and no debt.

Net income was $2.5 million ($0.22 per share), including a $2.0 million gain from LifeMD investment. The company faces headwinds from GLP-1 weight loss medications but highlighted positive clinical findings showing their OPTAVIA 5 & 1 Plan preserves 98% of lean mass. For Q3 2025, Medifast projects revenue between $70-90 million with EPS ranging from ($0.60) to $0.00.

LifeMD (NASDAQ:LFMD), a virtual primary care services provider, announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The event will take place at the InterContinental Boston from August 12-14, 2025.

Company management will engage in a fireside chat on August 13th at 8:30 AM ET and conduct one-on-one investor meetings during August 12-13. Interested investors can register through their Canaccord Genuity representative.